Andy Wardle is part of the biotech investment team in Venrock’s New York office. Prior to Venrock, Andy earned an MBA from Stanford Graduate School of Business and was involved in the formation of Mirum Pharmaceuticals, a biotech focused on childhood rare diseases.
Prior to business school, Andy spent two years at Boston Consulting Group (BCG) London as well as two years as a Physician focused on pediatrics. Andy has published several research articles in peer-reviewed journals. He received his medical degree and bachelor’s from the University of Bristol, graduating with First Class Honors.
Shelby Barada focuses on healthcare investments in Venrock’s New York office. Prior to joining Venrock, Shelby spent four years on J.P. Morgan’s Healthcare Investment Banking team in the firm’s San Francisco and London offices. While at J.P. Morgan, Shelby worked with biotech, pharma, and medtech companies on capital raising activities and M&A advisory. Shelby earned her MS in Biotechnology from Georgetown University and BS in Biochemistry from Washington and Lee University.
Lesley Kelly joined Venrock’s New York VHCP team in 2020 as Head Trader. In previous roles, she has traded healthcare on the buy-side and the sell-side–most recently joining from RBC Capital Markets. Prior to finance, Lesley served on active duty as an Intelligence Officer and Jumpmaster in the U.S. Army. She continues to support several Veteran philanthropies.
Lesley earned her B.S. from the University of Michigan, and an MBA from Owen Graduate School at Vanderbilt University.
Andrew Gottesdiener focuses on healthcare investments in Venrock’s New York office. Prior to joining Venrock, Andrew earned his MD at Weill Cornell Medical College during which he received an HHMI summer fellowship for basic science research. He also has an MBA from Columbia Business School where he graduated with Dean’s Honors and Distinction. Prior to medical school, Andrew worked in the Appel Alzheimer’s Disease Research Institute at Weill Cornell where he was developing preclinical gene therapy platforms to treat Alzheimer’s disease.
Andrew earned his AB in Economics from Washington University in St. Louis, where he graduated with College Honors and spent three years in the lab of Dr. David Holtzman studying the mechanisms of Alzheimer’s disease pathogenesis.
Alex Rosen focuses on biotechnology and pharmaceutical investments in Venrock’s New York office. Prior to joining Venrock, Alex earned an MD from the University of Pennsylvania School of Medicine, where he was elected to the Alpha Omega Alpha Honor Medical Society and the Gold Humanism Honor Society. He also earned an MBA in Health Care Management from the Wharton School, where he graduated with Honors and received a Kaiser Fellowship. He has published several articles in research journals and received Penn Med’s James B. Couch Prize for achievements in the dual disciplines of medicine and business.
In addition to his clinical training, Alex did internships at McKinsey & Company and in business development at Regeneron Pharmaceuticals, Inc.
He earned an AB in Economics from Princeton University, where he served as Class President for all four years, conducted independent research in health economics, and received the Moses Taylor Pyne Honor Prize, the highest general distinction conferred on an undergraduate.
Paul joined the public investment healthcare team at Venrock in 2015. He analyzes biotech and pharmaceutical companies over a large range of therapeutic areas. He was previously part of the research team at LifeSci Advisors, writing initiation reports for early-stage biotech companies. Prior to becoming part of the investment community, he was a graduate student at The Rockefeller University where he earned his PhD in chemical biology. His research has ranged from working in the nanoscience department at Sandia National Lab to studying small molecule inhibitors of bacterial infection. He obtained a BS in chemistry and molecular biology from Harvey Mudd College.
Nimish originally joined Venrock in 2013 and has been investing in public and private healthcare companies since 2010. He works predominantly on Venrock’s public and cross-over biotech funds.
He is currently a Board Observer for Dianthus. He previously served as a Board Director for InstilBio (NASDAQ: TIL) and Board Observer for LianBio (NASDAQ: LIAN), Biohaven Pharmaceuticals (NYSE: BHVN) and Viridian Therapeutics (NASDAQ: VRDN).
Nimish received his BS in pharmacy with honors from Rutgers College of Pharmacy, MPH from the Mailman School of Public Health at Columbia University, and MBA from Columbia Business School. He is a member of the Columbia Business School Healthcare and Pharmaceutical Management Advisory Board.